CAS: 162536-84-7; (S)-(2S,3R)-3,4-Dihydroxybutan-2-Yl 3-(4-(Benzyloxy)Phenyl)-2-((Tert-Butoxycarbonyl)Amino)Propanoate

该化合物是一种合成化合物,属于氨基酸衍生物类别,具体地说,是经过改良的铁质酸衍生物,其特点是三丁基氧碳基(Boc)保护组,通常用于丙酸合成以保护氨基组.苯基组的存在增强了其脂质性,使其在有机溶剂中更易溶解.过氧化物的功能表明,该化合物含有一种三成分的环球醚,可以反应,并经常参与各种化学变异.该复合物对医药化学和生物化学具有兴趣,特别是其潜在在药物开发中的应用和作为聚氨基合成的一个建筑块.其结构特性有助于其在生物系统中的再活性和特殊性,使它成为在药理学和有机合成领域进行研究的宝贵化合物.与许多百氧化合物一样,它可能展示独特的再活动模式,包括核糖素攻击,可以在合成路径上加以利用.

英文名称(S)-(2S,3R)-3,4-Dihydroxybutan-2-Yl 3-(4-(Benzyloxy)Phenyl)-2-((Tert-Butoxycarbonyl)Amino)Propanoate
中文名称(S)-(2S,3R)-3,4-二羟基丁烷-2-基3-(4-(苄氧基)苯基)-2-((叔丁氧基羰基)氨基)丙酸酯
其它别名(S)-[1'-(S)-N-B°C AMINO-2-[4-(BENZYLOXY)PHENYL]ETHYL]OXIRANE; ERYTHRO-N-T-BUTOXYCARBONYL-O-BENZYL-L-TYROSINE EPOXIDE; ERYTHRO-N-B°C-O-BENZYL-L-TYROSINE EPOXIDE; [2-(4-BENZYLOXY-PHENYL)-1(S)-(S)OXIRANYL-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER; (1S)-[1'-(S)-N-T-BUTOXYCARBONYL-AMINO-2-[4-(BENZYLOXY)PHENYL]ETHYL]OXIRANE; (1S)-(1'-(S)-N-B°C-AMINO-2-[4-(BENZYLOXY)PHENYL]ETHYL)OXIRANE
CAS编号162536-84-7
MFCD编号:MFCD04035566
分子式:C22H27NO4分子量:369.45
产品CID: 822536
产品分类有机原料→分子砌块→芳环类化合物→苯类化合物

相似结构搜索
InChIKey: WKKSCOKVTJQVPD-UHFFFAOYSA-N
1S/C22H27NO4/c1-22(2,3)27-21(24)23-19(20-15-26-20)13-16-9-11-18(12-10-16)25-14-17-7-5-4-6-8-17/h4-12,19-20H,13-15H2,1-3H3,(H,23,24)/t19-,20+/m0/s1
计算化学: 氢键受体数4.0氢键供体数1可旋转键数7

相似化合物

98737-29-2 98760-08-8 156474-22-5

MSDS等安全信息

GHS符号GHS07
警示词Warning
危险描述H302
防范说明P264-P270-P330-P501

上下游产品

CAS号174801-33-3 (2S,3S)-1-(4-(苄... | CAS号127132-32-5 (S)-3-(4-(苄氧基)苯... | CAS号152438-62-5 (S)-(1-(4-(苄氧基)...

合成工艺路线路线简述

📜(2S,3S)-1-(4-(苄氧基)苯基)-4-氯-3-羟基丁烷-2-氨基甲酸叔丁酯置于氢氧化钾体系中,用乙醇用作溶剂,化学反应生成赤配位-N-Boc-苄基-L-酪氨酸环氧化物
参考文献:Novel P1 Chain-Extended Hiv Protease Inhibitors Possessing Potent Anti-Hiv Activity And Remarkable Inverse Antiviral Resistance Profiles
标题:Novel P1 Chain-Extended Hiv Protease Inhibitors Possessing Potent Anti-Hiv Activity And Remarkable Inverse Antiviral Resistance Profiles
摘要:A Novel Series Of Tyro Si Ne-Derived Hiv Protease Inhibitors Was Synthesized And Evaluated For In Vitro Antiviral Activity Against Wild-Type Virus And Two Protease Inhibitor-Resistant Viruses. All Of The Compounds Had Wild-Type Antiviral Activities That Were Similar To Or Greater Than Several Currently Marketed Hiv Protease Inhibitors. In Addition,A Number Of Compounds In This Series Were More Potent Against The Drug-Resistant Mutant Viruses Than They Were Against Wild-Type Virus. (C) 2005 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmcl.2005.05.129